While it is well established that immunotherapies have unique toxicity profiles, effective management is not clearly defined and a challenge for many cancer teams. As evidence emerges on severity and onset of immune-related adverse events (irAEs), it is imperative that clinicians stay abreast of strategies to improve awareness, risk-assessment, monitoring, and management of irAEs including dosing modifications for immunotherapies. Experts will discuss these critical issues as well as the importance of a coordinated approach with multiple specialists for effective irAE management.
This activity is intended for medical, surgical, radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.
- Anticipate unique and common immune-related adverse events associated with immunotherapy across a wide range of solid tumors
- Implement expert-recommended best practices for managing adverse effects that can occur with immunotherapy
Approximate Time to Complete: 60 minutes
Credit Available: June 10, 2020 - February 28, 2021
Developed through a collaboration between SITC and PlatformQ.